Avadel Pharmaceuticals (FRA:AWK) YoY EBITDA Growth : 92.98% (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Avadel Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 92.98%.

Avadel Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2025 was €-0.02.

Avadel Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Avadel Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals YoY EBITDA Growth Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

125.35

-965.28

-23.03

-11.29

79.07

Avadel Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															39.80	85.29	103.41	94.10	92.98

Avadel Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Avadel Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-0.357	-	-1.706)	/	\| -1.706 \|
=	79.07 %

Avadel Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(-0.017	-	-0.242)	/	\| -0.242 \|
=	92.98 %

Avadel Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (FRA:AWK) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

AVDL:USA

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.